Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL6 | P41182 | 8/20 | 0.47 |
| ▸ | EGFR | P00533 | 9/20 | 0.39 |
| ▸ | ITK | Q08881 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 4/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 2/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15321035 | 0.93 | BCL6 (0.48) | BCL6EGFRITKBTKAXL | |
| SCHEMBL15337337 | 0.93 | BCL6 (0.48) | BCL6EGFRITKBTKAXL | |
| SCHEMBL17708228 | 0.87 | BCL6 (0.42) | BCL6EGFRITKBTKAXL | |
| SCHEMBL17708227 | 0.85 | EGFR (0.37) | BCL6EGFRITKBTKAXL | |
| SCHEMBL15321579 | 0.85 | EGFR (0.36) | BCL6EGFRITKBTKAXL | |
| SCHEMBL19527724 | 0.85 | EGFR (0.40) | BCL6EGFRITKBTKAXL | |
| SCHEMBL15321182 | 0.84 | ULK1 (0.43) | BCL6EGFRITKBTK | |
| SCHEMBL15337596 | 0.84 | ULK1 (0.43) | BCL6EGFRITKBTK | |
| SCHEMBL15321742 | 0.83 | EGFR (0.39) | BCL6EGFRITKBTK | |
| SCHEMBL15323103 | 0.83 | EGFR (0.39) | BCL6EGFRITKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2833889-B1 | PROTEIN KINASE C INHIBITORS AND USES THEREOF | RIGEL PHARMACEUTICALS INC (US) | 2017-11-01 | — | — | EP | claimed |
| US-9682976-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | MIDCAP FINANCIAL TRUST | 2016-09-08 | — | — | US | disclosed |
| US-9321763-B2 | Protein kinase C inhibitors and uses thereof | RIGEL PHARMACEUTICALS, INC. (US) | 2016-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160257681-A1 | Protein Kinase C Inhibitors and Uses Thereof | PRKCH, PRKCA, PRKCB | BCL6 1014/4885EGFR 2299/4885ITK 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.